The UAB Comprehensive Cancer Center is currently in its 39th year of continuous NCI CCSG funding. The Cancer Center has a well-established track record of translational research with a nnajor emphasis on investigator-initiated early phase 1 and II trials, many of which emanate from Cancer Center scientific discoveries. In addition, the Center has major strengths in the area of cancer health disparity research. Current funding levels are $106.1M total direct, $32.0M NCI, $48.2M other NIH, $8.7M peer-reviewed, and $17.1M non-peer reviewed. There are 244 members representing 10 schools and 33 departments. The Cancer Center's research enterprise is organized around seven programs, including three basic science programs - Tumor Immunology, Cancer Cell Biology, and Virology;two translational/dinical programs - Experimental Therapeutics and Neuro-Oncology;and two prevention and control programs - Cancer Chemoprevention and Cancer Control and Population Sciences. The Center's research enterprise is supported by 15 shared facilities that support and enhance our basic, clinical, translational, and prevention and control research by providing research technology, advanced genomics, biostatistics/bioinformatics, tissue procurement, human and animal imaging, and recruitment and retention of trial participants. Under current leadership, we have successfully recruited six new key leaders critical for a successful cancer research program and have recruited another 44 new cancer-focused faculty to various departments in the institution. Institutional support during this funding cycle has included $55M for recruitment and program building, $50M for renovation of cancer facilities including the Wallace Tumor Institute, the center of our cancer enterprise, and another $8.1 M from IMPACT funds to support recruitments. The Cancer Center has enhanced its translational research capabilities via a drug discovery and development initiative within the Experimental Therapeutics Program that incorporates the strength and resources of Southem Research into the Cancer Center via the Alabama Drug Discovery Alliance. In addition, the Cancer Center has forged a relationship with HudsonAlpha Institute for Biotechnology which provides the latest generation of high throughput genomic sequencing and collaborative expertise that will allow multiple programs to further understand the genetic footprints that impact therapeutic response, modify risk and thereby form the basis of individualized care.

Public Health Relevance

NCl-designated Comprehensive Cancer Centers are the centerpiece of the nation's effort to reduce cancer morbidity and mortality. The UAB Comprehensive Cancer Center serves as a major source for more effective approaches to prevention, diagnosis, treatment, and survivorship and as a source for delivery of these discoveries, public and professional education, and ultimately as a resource for the local, regional, and national community.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA013148-40S1
Application #
8533202
Study Section
Subcommittee G - Education (NCI)
Program Officer
Silkensen, Shannon M
Project Start
1997-03-28
Project End
2016-03-31
Budget Start
2012-04-01
Budget End
2013-03-31
Support Year
40
Fiscal Year
2012
Total Cost
$75,000
Indirect Cost
$23,805
Name
University of Alabama Birmingham
Department
Obstetrics & Gynecology
Type
Schools of Medicine
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Kim, H-G; LeGrand, J; Swindle, C S et al. (2017) The assembly competence domain is essential for inv(16)-associated acute myeloid leukemia. Leukemia 31:2267-2271
Miller, Aubrey L; Garcia, Patrick L; Pressey, Joseph G et al. (2017) Whole exome sequencing identified sixty-five coding mutations in four neuroblastoma tumors. Sci Rep 7:17787
Childers, Noel K; Grenett, Hernan; Morrow, Casey et al. (2017) Potential Risk for Localized Aggressive Periodontitis in African American Preadolescent Children. Pediatr Dent 39:294-298
Kasten, Benjamin B; Arend, Rebecca C; Katre, Ashwini A et al. (2017) B7-H3-targeted 212Pb radioimmunotherapy of ovarian cancer in preclinical models. Nucl Med Biol 47:23-30
Prince, Andrew C; Jani, Aditi; Korb, Melissa et al. (2017) Characterizing the detection threshold for optical imaging in surgical oncology. J Surg Oncol 116:898-906
McConnell, Matthew; Feng, Shengmei; Chen, Wei et al. (2017) Osteoclast proton pump regulator Atp6v1c1 enhances breast cancer growth by activating the mTORC1 pathway and bone metastasis by increasing V-ATPase activity. Oncotarget 8:47675-47690
Kumar, Ranjit; Yi, Nengjun; Zhi, Degui et al. (2017) Identification of donor microbe species that colonize and persist long term in the recipient after fecal transplant for recurrent Clostridium difficile. NPJ Biofilms Microbiomes 3:12
Van Beusecum, J P; Zhang, S; Cook, A K et al. (2017) Acute toll-like receptor 4 activation impairs rat renal microvascular autoregulatory behaviour. Acta Physiol (Oxf) 221:204-220
Ghosh, Arindam P; Willey, Christopher D; Anderson, Joshua C et al. (2017) Kinomic profiling identifies focal adhesion kinase 1 as a therapeutic target in advanced clear cell renal cell carcinoma. Oncotarget 8:29220-29232
Shah, Spandan; Gibson, Andrew W; Ji, Chuanyi et al. (2017) Regulation of FcR? function by site-specific serine phosphorylation. J Leukoc Biol 101:421-428

Showing the most recent 10 out of 692 publications